A long-lasting diabetes medicine helper

Original Title

A novel exendin-4 human serum albumin fusion protein, E2HSA, with an extended half-life and good glucoregulatory effect in healthy rhesus monkeys.

Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms

Summary

Scientists made a new medicine called E2HSA by combining a diabetes drug part with a blood protein to make it last longer in the body. They tested it in labs and monkeys.

Sign up to see full results

Get access to research results, context, and detailed analysis.

Surprising Findings

E2HSA retains biological activity despite being less potent than exendin-4

Fusion proteins often lose function due to structural changes, but here the drug still activated insulin release and reduced glucose—even with lower in vitro potency.

Practical Takeaways

Stay informed about long-acting GLP-1 therapies in development—they may offer fewer injections and better adherence in the future.

low confidence

Unlock Full Study Analysis

Sign up free to access quality scores, evidence strength analysis, and detailed methodology breakdowns.